====== Arsenic trioxide 60μM R08 exp449 ====== ==== Mechanism of Action ==== Induces degradation of aberrant PML-RAR‘± fusion protein in acute promyelocytic leukemia * **Class / Subclass 1:** Environmental Stresses / Heavy Metal * **Class / Subclass 2:** Signal Transduction / Apoptosis Inducer ==== Technical Notes ==== * **PubChem Name:** %%2,4,6,8,9,10-Hexaoxa-1,3,5,7-tetraarsatricyclo[3.3.1.13,7]decane%% * **Synonyms:** N/A * **CAS #:** 1327-53-3 * **PubChem CID:** [[https://pubchem.ncbi.nlm.nih.gov/compound/518605|518605]] * **IUPAC:** %%2,4,6,8,9,10-hexaoxa-1,3,5,7-tetrarsatricyclo[3.3.1.13,7]decane%% * **INCHI Name:** InChI=1S/As4O6/c5-1-6-3-8-2(5)9-4(7-1)10-3 * **INCHI Key:** KTTMEOWBIWLMSE-UHFFFAOYSA-N * **Molecular Weight:** 395.68 * **Canonical SMILES:** O1[As]2O[As]3O[As]1O[As](O2)O3 * **Isomeric SMILES:** N/A * **Molecular Formula:** As4O6 {{:chemogenomics:structures:chem-0260.svg?nolink}} * **Supplier Name:** Toronto Research Chemicals * **Catalog #:** A774130 * **Lot #:** 14-CGS-186-1 * **XRPD:** Expected As2O3; found As2O3 * **Platform ID:** Arsenic_Oxide * **Min:** 14.1313; **Max:** 99.7631 {{:chemogenomics:dose_response:dr_599.png?nolink&500 |}} \\ \\ \\ \\ |< 300px 100px 200px >| ^ IC ^ Concentration (µM) ^ | IC10 |30.7900 | | IC20 |46.5800 | | IC30 |61.3300 | | IC40 |76.8500 | | IC50 |94.5200 | | IC60 |116.3000 | | IC70 |145.7000 | | IC80 |191.8000 | | IC90 |290.2000 | \\ ==== Screen Summary ==== * **Round**: 08 * **Dose**: 60µM * **Days of incubation**: 8 * **Doublings**: 4.5 * **Numbers of reads**: 16171461 ==== Screen Results ==== ^Sensitive/Resistant hits (FDR<0.05)^CRANKS^Score Plot^Top 30 Genes^Screen Similarity^Top 30 Sensitive GO terms^Top 30 Resistant GO terms^ |2/8|[[https://files.tyerslab.com/files/public/chemogenomics/cranks/Arsenic_trioxide_60uM_Round-8_exp449.txt|Scores]]|||||| {{:chemogenomics:cranks_plots:exp449.png?nolink}} ^Gene^CRANKS Score^FDR^ |[[:human_genes:G:GCLM|GCLM]]|-3.74|<0.01| |[[:human_genes:A:ABCC1|ABCC1]]|-3.29|<0.01| |[[:human_genes:B:BAZ1A|BAZ1A]]|-2.56|0.06| |[[:human_genes:D:DDI2|DDI2]]|-2.55|0.06| |[[:human_genes:G:GTF3C1|GTF3C1]]|-2.55|0.23| |[[:human_genes:R:RAPH1|RAPH1]]|-2.54|0.06| |[[:human_genes:K:KPNB1|KPNB1]]|-2.49|0.38| |[[:human_genes:G:GSS|GSS]]|-2.39|0.12| |[[:human_genes:V:VPS51|VPS51]]|-2.35|0.23| |[[:human_genes:C:CENPT|CENPT]]|-2.32|0.26| |[[:human_genes:N:NGLY1|NGLY1]]|-2.31|0.15| |[[:human_genes:K:KIF18A|KIF18A]]|-2.31|0.15| |[[:human_genes:V:VBP1|VBP1]]|-2.28|0.16| |[[:human_genes:S:SEPSECS|SEPSECS]]|-2.26|0.22| |[[:human_genes:M:MAN2A1|MAN2A1]]|-2.23|0.19| |[[:human_genes:E:EP400|EP400]]|-2.21|0.33| |[[:human_genes:C:C8orf47|C8orf47]]|-2.21|0.19| |[[:human_genes:B:BRPF1|BRPF1]]|-2.20|0.19| |[[:human_genes:F:FAM69A|FAM69A]]|-2.18|0.19| |[[:human_genes:T:TMEM80|TMEM80]]|-2.16|0.20| |[[:human_genes:Z:ZNF793|ZNF793]]|-2.12|0.22| |[[:human_genes:T:TSSC1|TSSC1]]|-2.10|0.23| |[[:human_genes:K:KALRN|KALRN]]|-2.07|0.33| |[[:human_genes:N:NPTN|NPTN]]|-2.07|0.23| |[[:human_genes:W:WNT3A|WNT3A]]|-2.07|0.33| |[[:human_genes:C:CDIPT|CDIPT]]|-2.07|0.57| |[[:human_genes:C:CYLD|CYLD]]|-2.01|0.30| |[[:human_genes:G:GCLC|GCLC]]|-2.00|0.31| |[[:human_genes:A:AAED1|AAED1]]|-1.99|0.38| |[[:human_genes:P:PLEKHJ1|PLEKHJ1]]|-1.95|0.33| |[[:human_genes:C:CD72|CD72]]|2.05|0.24| |[[:human_genes:P:PMVK|PMVK]]|2.06|0.29| |[[:human_genes:C:CDC20|CDC20]]|2.07|0.44| |[[:human_genes:A:ANP32A|ANP32A]]|2.08|0.27| |[[:human_genes:A:ALG1L|ALG1L]]|2.09|0.21| |[[:human_genes:C:C8orf59|C8orf59]]|2.10|0.47| |[[:human_genes:P:PAX2|PAX2]]|2.11|0.21| |[[:human_genes:F:FOXD4L1|FOXD4L1]]|2.12|0.27| |[[:human_genes:C:CBLL1|CBLL1]]|2.13|0.27| |[[:human_genes:R:RPS3|RPS3]]|2.14|0.30| |[[:human_genes:U:UBA6|UBA6]]|2.14|0.20| |[[:human_genes:U:UTY|UTY]]|2.18|0.17| |[[:human_genes:C:CXorf56|CXorf56]]|2.21|0.21| |[[:human_genes:N:NAA15|NAA15]]|2.21|0.21| |[[:human_genes:N:NANS|NANS]]|2.25|0.17| |[[:human_genes:E:EIF4A1|EIF4A1]]|2.26|0.20| |[[:human_genes:S:SLC25A1|SLC25A1]]|2.33|0.12| |[[:human_genes:T:TMEM126B|TMEM126B]]|2.37|0.17| |[[:human_genes:S:SLC19A1|SLC19A1]]|2.49|0.17| |[[:human_genes:R:RNASEH2A|RNASEH2A]]|2.50|0.17| |[[:human_genes:R:RPL35A|RPL35A]]|2.52|0.53| |[[:human_genes:A:AK3|AK3]]|2.66|0.02| |[[:human_genes:C:CNBP|CNBP]]|2.69|0.02| |[[:human_genes:Y:YLPM1|YLPM1]]|2.71|0.17| |[[:human_genes:U:UTP14A|UTP14A]]|2.74|0.04| |[[:human_genes:H:HSPA14|HSPA14]]|3.25|<0.01| |[[:human_genes:K:KMT2D|KMT2D]]|3.25|<0.01| |[[:human_genes:F:FAM122A|FAM122A]]|3.42|<0.01| |[[:human_genes:K:KEAP1|KEAP1]]|4.24|<0.01| |[[:human_genes:R:RRM2|RRM2]]|4.31|0.04| ^Screen^Correlation^Plot^ |[[:results:exp529|Thimerosal 0.85μM R08 exp529]]|0.052|| |[[:results:exp30|Rapamycin 10μM R00 exp30]]|0.051|| |[[:results:exp307|Rapamycin 2μM plus Cyclosporin-A 3μM R07 exp307]]|0.051|| {{:chemogenomics:comparison_plots:exp449_vs_exp529.png?nolink |}} {{:chemogenomics:comparison_plots:exp30_vs_exp449.png?nolink |}} {{:chemogenomics:comparison_plots:exp307_vs_exp449.png?nolink |}} ^GO Term^Fold Change^Genes^ |nonribosomal peptide biosynthetic process|136.56|GCLM,GSS,GCLC| |acid-amino acid ligase activity|91.04|GCLM,GSS,GCLC| No GO term hits below threshold. (FDR <0.05)